Synaptogenix Management
Management criteria checks 4/4
Synaptogenix's CEO is Alan Tuchman, appointed in Dec 2020, has a tenure of 3.92 years. total yearly compensation is $303.35K, comprised of 73.2% salary and 26.8% bonuses, including company stock and options. directly owns 0.097% of the company’s shares, worth $3.43K. The average tenure of the management team and the board of directors is 8.2 years and 5.3 years respectively.
Key information
Alan Tuchman
Chief executive officer
US$303.3k
Total compensation
| CEO salary percentage | 73.2% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 8.2yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$3m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | US$303k | US$222k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$750k | US$222k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$222k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$14m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$184k | US$184k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$36k | US$36k | -US$15m |
Compensation vs Market: Alan's total compensation ($USD303.35K) is below average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.
CEO
Alan Tuchman (77 yo)
3.9yrs
Tenure
US$303,347
Compensation
Dr. Alan J. Tuchman M.D., MBA(FAAN), serves as the Chief Executive Officer at Synaptogenix, Inc. (formerly, Neurotrope Bioscience, Inc.), since December 2020 and has been its Director since December 02, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | US$303.35k | 0.097% $ 3.4k | |
| President | 8.2yrs | US$375.00k | 0.10% $ 3.7k | |
| CFO, Executive VP | 11.4yrs | US$568.92k | 0.098% $ 3.5k |
8.2yrs
Average Tenure
77yo
Average Age
Experienced Management: SNPX's management team is seasoned and experienced (8.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | US$303.35k | 0.097% $ 3.4k | |
| President | 3.9yrs | US$375.00k | 0.10% $ 3.7k | |
| Independent Chairman of the Board | 8.3yrs | US$254.94k | 0.11% $ 4.0k | |
| Chairman of the Scientific Advisory Board | 3.2yrs | US$449.77k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Vice-Chairman of the Board | 5.3yrs | US$114.94k | 0.097% $ 3.4k | |
| Independent Director | 5.9yrs | US$74.94k | 0.080% $ 2.8k | |
| Independent Director | 8yrs | US$74.94k | 0.081% $ 2.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.3yrs
Average Tenure
66yo
Average Age
Experienced Board: SNPX's board of directors are considered experienced (5.3 years average tenure).